Scientists at acib and the University of Natural Resources Vienna develop world’s first continuous purification method for valuable drugs. This will lead to significantly reduced production costs and to cheaper pharmaceuticals that are affordable for non-privileged health care systems.
Imagine a dear relative suffering from cancer – and you could not afford a treatment because the drugs are too expensive. The Austrian Centre of Industrial Biotechnology (acib) developed a method with the power to reduce production costs of highly valued drugs significantly.
Without antibodies we would be at the mercy of pathogens or cancer cells. Therapeutic antibodies are used as passive vaccines, for cancer therapy or for controlling autoimmune diseases such as multiple sclerosis. According to “bccresearch.com” the global market for antibody drugs was worth nearly 70 billion USD in 2014 and should rise to 122 billion USD until 2019.
Two thirds of those molecules are produced biotechnologically using Chinese hamster ovary cells (CHO). Actually the major cost factor for industry is purification using “protein A” affinity chromatography where tens of thousands of liters of culture volume have to be processed annually. About 80 % of the production costs fall upon purification.
Here this new purification method comes into play. Researchers from the Austrian Centre of Industrial Biotechnology (acib) and the University of Natural Resources and Life Sciences Vienna (BOKU) developed the world’s first downstream processing method for recombinant antibodies from clarified CHO cultures. From a technical view, the purification method combines a Calcium-Phosphate flocculation with a subsequent cold ethanol precipitation in a tubular reactor realized as a double-pipe heat exchanger that is operated in counter-current flow.
A feasibility study exemplified by the purification of immune globulin G (IgG) shows that the continuous method can compete with “protein A” affinity chromatography in terms of yield and outperforms chromatography according to the speed of operation. A further advantage is that the operation parameters can be easily transferred from the actually used batch to the continuous approach. In combination with a prior concentration step the new method is perfect for purification of low titer supernatants. “Our method shows great potential as a new platform technology for the pharmaceutical industry”, says Prof. Alois Jungbauer, who is in negotiations with several international companies about building pilot plants.
The Latest on: Drug production
via Google News
The Latest on: Drug production
- Antibody-Drug Conjugates Market Size to Reach USD 20.01 Billion in 2028 | Emergen Researchon October 13, 2021 at 2:22 am
According to Emergen Research, the global antibody-drug conjugates market size was USD 3.18 billion in 2020 and is expected to reach USD 20.01 billion in 2028 and register a revenue CAGR of 25.8% ...
- $14.4+ Billion Erythropoietin Drugs Market Outlook, 2021-2028 | Increasing Level of Awareness About the Benefits of EPO Therapeutics - ResearchAndMarkon October 13, 2021 at 1:59 am
The "Erythropoietin Drugs Market by Product Type and Application: Global Opportunity Analysis and Industry Forecast, 2021-2028" report has been added to ResearchAndMarkets.com's offering. The global ...
- Prescription Drug Safety Risks Hidden, Hypochondria Created by Marketingon October 13, 2021 at 1:45 am
If you’re like most people, you never heard of the prescription drug Humira until 2013. That’s when Abbott Laboratories spun off AbbVie, to aggressively ...
- The Dangerous Irrationality of How Indian Regulators Classify Substandard Drugson October 12, 2021 at 8:21 pm
While regulators deal with substandard drugs in a way that favours the industry, Indian patients are getting the short end of the stick.
- Arthritis drug in low supply after becoming treatment for COVID-19on October 12, 2021 at 8:13 pm
Arthritis patients are struggling to receive certain treatments due to the nationwide shortage of the drug Actemra. The drug is in low supply after becoming a treatment for COVID-19 patients.
- Eco-friendly drug production Nobel winner's proudest achievementon October 6, 2021 at 12:16 pm
Princeton professor David MacMillan on Wednesday won the Nobel Chemistry Prize for his work developing a new tool to scale up chemical reactions in an environmentally friendly way, known as ...
- Drug-Coated Balloons Market Report Provides Marketing Channel, Distributors, Customers and Manufacturing Process Analysis 2021 to 2027on October 6, 2021 at 4:38 am
Oct 06, 2021 (The Expresswire) -- "Final Report will add the analysis of the impact of COVID-19 on this industry" The report analyse the growth rate of ...
- Orphan Drugs Market Size, Share, Manufacturing Cost Structure, Revenue, Up-to-date Industry Data and Growth Status Report 2021 to 2025on October 6, 2021 at 4:32 am
Oct 06, 2021 (The Expresswire) -- "Final Report will add the analysis of the impact of COVID-19 on this industry" Industries around the world are aiming ...
- Manganese Makes Its Mark in Drug Manufacturingon October 6, 2021 at 1:01 am
Rice University lab discovers that manganese simplifies the process of synthesizing fluoroketones, precursor molecules used in the manufacturing of drugs.
- TETFund to support four agencies on drug productionon October 5, 2021 at 5:00 pm
Kolawole Published 6 October 2021The Tertiary Education Trust Fund on Wednesday said it would be providing “mega research support” to four public agencies, led by the National Institute for ...
via Bing News